Phase III study: Pembrolizumab demonstrates superior survival, progression free survival and overall response rate compared to Ipilimumab
MSD (known as Merck & Co Inc. in the United States and Canada) has announced results from the randomised, pivotal Phase 3 study, KEYNOTE-006 which compared pembrolizumab to ipilimumab in patients...